polyestradiol phosphate (Estradurin)

01/01/1971 - "Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol."
03/14/1959 - "[Clinico-biological aspects of several cases of carcinoma of the prostate treated with polyestradiol phosphate (PEP)]."
05/31/1957 - "Treatment of prostatic carcinoma with a new, water-soluble oestrogenic preparation, estradurin."
02/01/1957 - "Polyestradiol phosphate for carcinoma of the prostate: a clinical study."
01/01/1956 - "Polyestradiol phosphate for carcinoma of the prostate: a clinical study."

08/01/2001 - "There was complete relief from hot flashes in 50% of the men on polyestradiol phosphate during followup compared with none on androgen ablation. "
08/01/2001 - "The data in this study enable us to provide thorough individual information to patients on the risk and grade of expected distress and duration of hot flashes during polyestradiol phosphate or complete androgen ablation treatment."
08/01/2001 - "Endocrine treatment with polyestradiol phosphate induced fewer and less distressing hot flashes than complete androgen ablation. "
08/01/2001 - "In the polyestradiol phosphate group the frequency of and distress due to hot flashes were significantly lower than in the androgen ablation group. "
08/01/2001 - "The incidence of hot flashes was 30.1% and 74.3% in the polyestradiol phosphate and complete androgen ablation groups, respectively (p <0.001). "

01/01/1999 - "Parenteral polyestradiol phosphate is still a cheap potential treatment for advanced prostatic cancer, but further studies should be conducted to establish its future role, e.g. "
01/01/1999 - "The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium."
01/01/1988 - "Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate."
08/01/1960 - "[Estradurin in the treatment of cancer of the prostate]."
03/01/2007 - "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy."

05/01/1995 - "We found that patients with moderately well differentiated cancer (stage greater than T0a) who received early treatment with estramustine phosphate had the lowest risk of metastases or death from prostatic cancer, while those with well differentiated cancer (stage greater than T0a) did best on early polyestradiol phosphate plus ethinylestradiol treatment."
03/01/1984 - "Prolactin concentrations were increased in vivo by (a) direct intraperitoneal injection of ovine prolactin; (b) subcutaneous implantation of diethylstilbestrol-containing silastic capsules to produce pituitary prolactin secreting tumors; or (c) a single subcutaneous injection of polyestradiol phosphate, a long-acting estrogen. "

05/01/1995 - "We found that patients with moderately well differentiated cancer (stage greater than T0a) who received early treatment with estramustine phosphate had the lowest risk of metastases or death from prostatic cancer, while those with well differentiated cancer (stage greater than T0a) did best on early polyestradiol phosphate plus ethinylestradiol treatment."
01/01/2008 - "To compare parenteral estrogen therapy in the form of high-dose polyestradiol phosphate (PEP; Estradurin) with combined androgen deprivation (CAD) in the treatment of prostate cancer patients with skeletal metastases. "